Chengdu Kanghua Biological Products Co., Ltd. (SHE:300841)
China · Delayed Price · Currency is CNY 50.90
-1.84 (-3.49%)
Sep 2, 2026, 3:04 PM CST
SHE:300841 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,219 | 1,165 | 1,326 | 1,577 | 1,446 | 1,292 |
Other Revenue | 0.06 | 0.09 | 106.25 | 0 | 0.32 | - |
| 1,219 | 1,165 | 1,432 | 1,577 | 1,447 | 1,292 | |
Revenue Growth | 3.81% | -18.64% | -9.22% | 9.03% | 11.94% | 24.44% |
Cost of Revenue | 120.99 | 100.89 | 84.64 | 104.9 | 101.84 | 85.7 |
Gross Profit | 1,098 | 1,064 | 1,347 | 1,472 | 1,345 | 1,207 |
Selling, General & Admin | 693.11 | 678.2 | 658.4 | 601.15 | 510.78 | 498.42 |
Research & Development | 104.01 | 118.39 | 132.05 | 253.03 | 179.94 | 78.88 |
Other Operating Expenses | 11.89 | 10.19 | 9.99 | 9.24 | 8.23 | 7.14 |
Operating Expenses | 806.81 | 817.83 | 815.6 | 872.01 | 733.05 | 592.78 |
Operating Income | 291.63 | 246.29 | 531.64 | 600.49 | 611.84 | 613.96 |
Interest Expense | -1.64 | -3.68 | -5.38 | -4.81 | -3.19 | -0.07 |
Interest & Investment Income | 11.26 | 13.58 | 13.17 | 12.94 | 19.26 | 25.93 |
Currency Exchange Gain (Loss) | -0.02 | 0.04 | 1.68 | 0.21 | 0.05 | -0.01 |
Other Non Operating Income (Expenses) | -7.46 | -0.47 | -15.02 | -1.28 | -1.44 | -0.19 |
EBT Excluding Unusual Items | 293.77 | 255.76 | 526.1 | 607.54 | 626.53 | 639.62 |
Gain (Loss) on Sale of Investments | -0.91 | -3.57 | -59.73 | -31.6 | 51.89 | 269.32 |
Gain (Loss) on Sale of Assets | - | -0.01 | -1.79 | -0.19 | - | -0.11 |
Asset Writedown | -6.4 | -0.12 | -0.02 | -0.3 | - | - |
Other Unusual Items | 6.66 | 7.68 | 2.45 | -1.47 | 5.37 | 6.75 |
Pretax Income | 293.13 | 259.74 | 467.02 | 573.99 | 683.79 | 915.58 |
Income Tax Expense | 46.6 | 39.85 | 68.37 | 64.78 | 85.73 | 86.1 |
Net Income | 246.53 | 219.9 | 398.65 | 509.22 | 598.07 | 829.48 |
Net Income to Common | 246.53 | 219.9 | 398.65 | 509.22 | 598.07 | 829.48 |
Net Income Growth | 19.31% | -44.84% | -21.71% | -14.86% | -27.90% | 103.28% |
Shares Outstanding (Basic) | 130 | 130 | 132 | 134 | 134 | 135 |
Shares Outstanding (Diluted) | 130 | 130 | 132 | 134 | 134 | 135 |
Shares Change | -0.14% | -1.30% | -1.56% | -0.17% | -0.46% | 13.94% |
EPS (Basic) | 1.90 | 1.69 | 3.03 | 3.81 | 4.47 | 6.16 |
EPS (Diluted) | 1.90 | 1.69 | 3.03 | 3.81 | 4.46 | 6.16 |
EPS Growth | 19.48% | -44.11% | -20.47% | -14.71% | -27.57% | 78.42% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 425.53 | 308.92 | 427.94 | 416.71 | -224.24 | -184.61 |
Free Cash Flow Per Share | 3.27 | 2.38 | 3.25 | 3.12 | -1.67 | -1.37 |
Dividend Per Share | 0.500 | 0.500 | 1.000 | 2.000 | 0.500 | 1.000 |
Dividend Growth | -50.00% | -50.00% | -50.00% | 300.00% | -50.00% | 49.99% |
Gross Margin | 90.08% | 91.34% | 94.09% | 93.35% | 92.96% | 93.37% |
Operating Margin | 23.91% | 21.14% | 37.13% | 38.07% | 42.29% | 47.50% |
Profit Margin | 20.22% | 18.88% | 27.84% | 32.28% | 41.34% | 64.18% |
Free Cash Flow Margin | 34.89% | 26.52% | 29.89% | 26.42% | -15.50% | -14.28% |
EBITDA | 366.03 | 319.8 | 596.88 | 651.5 | 643.37 | 629 |
EBITDA Margin | 30.02% | 27.45% | 41.69% | 41.30% | 44.47% | 48.67% |
D&A For EBITDA | 74.4 | 73.51 | 65.23 | 51.02 | 31.53 | 15.04 |
EBIT | 291.63 | 246.29 | 531.64 | 600.49 | 611.84 | 613.96 |
EBIT Margin | 23.91% | 21.14% | 37.13% | 38.07% | 42.29% | 47.50% |
Effective Tax Rate | 15.90% | 15.34% | 14.64% | 11.29% | 12.54% | 9.40% |
Revenue as Reported | 681.08 | 1,165 | 1,432 | 1,577 | 1,447 | 1,292 |
Advertising Expenses | - | - | - | 398.03 | 346.56 | 344.4 |